Pharmaceutical

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former company. The device is being currently manufactured for Takeda’s ulcerative colitis and Crohn's disease drug, Entyvio, which is presently being administered through intravenous infusion. The drug maker is already searching to deliver this biologic in a new way, and the subcutaneous formulation is being tested in a phase 3 trial. Under this agreement, Portal stand...